Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • China sharply rebukes US over decision to shoot down ‘spy’ balloon
    • Ukraine prepares for renewed Russian offensive
    • China’s military keeps rivals on edge with balloon strategy
    • Violent end to spy balloon flight dashes chance of US-China reset
    • China steps up condemnation of balloon shooting by US
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Liz Truss draws fire after blaming ‘economic establishment’ for her downfall
    • Rishi Sunak warned of Tory backlash if he tries to take UK out of ECHR
    • Cradle to grave: is Britain’s NHS broken?
    • Breakdown of gas storage talks leaves UK exposed to price surges, say experts
    • Cost of fixed-rate mortgages set to fall as UK inflation outlook brightens
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Adani ditched Big Four auditor for UK subsidiaries
    • The sheikh’s empire driving Abu Dhabi’s meteoric stock market rise
    • Baillie Gifford sheds more than £100bn in assets in 2022
    • Rothschild family plans to take Rothschild & Co private
    • Pension schemes advised to sell LDI funds after gilt chaos
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Live news: Premier League accuses Manchester City of financial regulation breaches
    • A bipolar currency regime will replace the dollar’s exorbitant privilege
    • Baillie Gifford sheds more than £100bn in assets in 2022
    • Investors pile into market rally as economic slowdown risk ebbs
    • Can the pioneer of blockchain gaming survive the crypto winter?
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The case for a land value tax is overwhelming
    • How the spy balloon popped a US-China rapprochement
    • Pakistan is on the brink
    • The worst airport in the world
    • Apple blundered when it killed off Dark Sky
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Barclays chief: the life lessons I have discovered during cancer treatment
    • Management research: why are so few of its ideas taken up?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • After hours with 10 Foot, London’s most notorious graffiti writer
    • My downshift to deepest Spain
    • Rugby superstar Siya Kolisi: ‘I’ve got no ego at all’
    • Germany grapples with the limits of pacifism
    • The secrets of the Mercedes-Benz Holy Halls
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Dementia

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 11 January, 2023
    Anjana Ahuja
    New Alzheimer’s drug straddles uneasy gulf between help and harm

    For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

  • Thursday, 29 December, 2022
    Biogen Inc
    Congress faults US regulator’s approval of Biogen Alzheimer’s drug

    Committees cite inappropriate collaboration between FDA and drugmaker

  • Friday, 2 December, 2022
    Pharmaceuticals sector
    Swedish scientist behind Alzheimer’s drug has big ambitions

    Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

  • Friday, 2 December, 2022
    The editorial board
    A glimmer of hope in treating Alzheimer’s disease

    Dementia drug development, diagnostics and delivery still require much more investment

  • Wednesday, 30 November, 2022
    Eisai says Alzheimer’s drug did not cause deaths of trial patients

    Japanese company refuses to rule out possibility treatment contributed to brain bleeds

  • Tuesday, 29 November, 2022
    Eisai Co Ltd
    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Shares fall 11% following two patient deaths in trials of lecanemab

  • Monday, 28 November, 2022
    LexDrugs research
    Dementia/Biogen: causal controversy means investors must take a stance Premium content

    The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

  • Monday, 14 November, 2022
    Roche Holding AG
    Roche late-stage Alzheimer’s trials end in failure

    Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

  • Sunday, 13 November, 2022
    Insurance
    AI is giving insurers godlike powers, says Sompo chief

    Access to large data sets means predictions are far more accurate in reducing risk

  • Monday, 24 October, 2022
    Special ReportFT Health: Communicable Diseases
    Evidence builds of viruses’ role in Alzheimer’s disease

    Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus

  • Wednesday, 28 September, 2022
    Pharmaceuticals sector
    Biogen and Eisai shares surge after Alzheimer’s drug trial success

    Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

  • Friday, 23 September, 2022
    Health sector
    Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

    Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

  • Monday, 22 August, 2022
    Medical science
    Electrical brain stimulation improves memory in elderly, research finds

    Study could be used to help boost cognitive performance of people developing Alzheimer’s disease

  • Wednesday, 17 August, 2022
    Coronavirus pandemic
    Covid can cause brain disorders two years after infection, study shows

    Long-term effects are generally less in children, although infection doubles risk of epilepsy

  • Wednesday, 18 May, 2022
    Coronavirus pandemic
    How can Covid-19 affect the human brain?

    Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

  • Sunday, 17 April, 2022
    Anjana Ahuja
    Hasty approval for Alzheimer’s drug offers a cautionary tale

    FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

  • Friday, 8 April, 2022
    News in-depthPharmaceuticals sector
    US imposes strict curbs on contentious Biogen Alzheimer’s treatment

    Agency that controls spending by government health schemes will not fund drug for most patients

  • Thursday, 13 January, 2022
    ReviewNon-Fiction
    What I Wish People Knew About Dementia — uplifting depiction

    Practical and reassuring tale written with eloquence and insight about a disease which for years was presumed to rob sufferers of sentience

  • Wednesday, 20 October, 2021
    Biogen Inc
    Biogen sells just $300,000 worth of contentious Alzheimer’s drug

    Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

  • Wednesday, 1 September, 2021
    Scientists warn that Covid will accelerate ‘dementia pandemic’

    Experts point to mounting evidence that the virus can cause long-term brain damage in some patients

  • Thursday, 22 July, 2021
    Biogen Inc
    Biogen defends contentious $56,000 Alzheimer’s drug

    Pharma group blames ‘misinformation’ for overshadowing approval of therapy

  • Sunday, 18 July, 2021
    Coronavirus treatment
    UK to study causes, diagnosis and treatment of long Covid

    Research to focus on future health burden as variants and looser restrictions drive up cases

  • Friday, 9 July, 2021
    US Food & Drug Administration
    FDA calls for probe of staff involved in divisive Alzheimer’s approval

    US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Wednesday, 16 June, 2021
    Pharmaceuticals sector
    Biogen’s Japanese partner calls for global action on Alzheimer’s

    Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In